Treatment of Pancreatic Adenocarcinoma by Combining Contrast Agent and Gemitabine Under Sonification
The primary outcome is monitor for toxicity effect for the combination therapy.
Interventional
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Toxic effects and safety of gemcitabine in combination with US contrast agent under sonication with gemcitabine alone.
To evaluate and compare the toxic effects and safety of gemcitabine in combination with US contrast agent under sonication with gemcitabine alone.
Two years
Yes
Georg Dimcevski
Principal Investigator
Haukeland University Hospital
Norway: Ethics Committee
2011/1601
NCT01674556
February 2012
December 2014
Name | Location |
---|